66th ASH Annual Meeting: Clinical Trial Approaches in Clonal Hematopoiesis

Symposia: Scientific Workshop on Clonal Hematopoiesis Scientific Workshops

Room 8 (San Diego Convention Center)

Moderator:

and Mrinal M. Patnaik, MD, MBBS, Mayo Clinic

Disclosures:

Patnaik: Kura Oncology: Research Funding; Epigenetix: Research Funding; Solu therapeutics: Research Funding; Polaris: Research Funding; StemLine: Research Funding; Astra Zeneca: Membership on an entity's Board of Directors or advisory committees.

The speakers will address the crucial question of how we can reduce or prevent Clonal Hematopoiesis (CH) by targeting different pathways involved in its pathogenesis. This session will open discussion on potential large scale collaborative trials in CH prevention.

Moderator Introduction

Mrinal M. Patnaik, MD, MBBS

Mayo Clinic, Rochester, MN

Targeting TET2 in Clonal Hematopoiesis

Luisa Cimmino, PhD

Biochemistry and Molecular Biology, University of Miami-Miller School of Medicine, Miami, FL

Addressing Inflammaging As Secondary Prevention in Clonal Hematopoiesis

Amit Verma, MD

Albert Einstein College of Medicine, Bronx, NY; Montefiore Einstein Comprehensive Cancer Center, Blood Cancer Institute, Department of Oncology, Montefiore Health System, Inc., Bronx, NY

Serendipity and Lessons Learned about Clonal Hematopoiesis in the Cantos Study

David P. Steensma, MD

Ajax Therapeutics, Cambridge, MA

Panel Discussion

See more of: Scientific Workshop on Clonal Hematopoiesis
See more of: Scientific Workshops

<< Previous Session | Next Session >>